Rena Conti
Dean’s Research Scholar
Associate Professor, Markets, Public Policy, and Law
Publications
Minje, P., Carson, A., Erin, F., Conti, R. (In Press). “Stockpiling Medicines at the Onset of the COVID-19 Pandemic: An Empirical Analysis of National Prescription Drug Sales and Prices”, Management Science
Levengood, T., Conti, R., Cahill, S., Cole, M. (2024). “Assessing the Impact of the 340B Drug Pricing Program: A Scoping Review of the Empirical, Peer-Reviewed Literature.”, Milbank Q, 102 (2), 429-462
Vogel, M., Kakani, P., Chandra, A., Conti, R. (2024). “Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act.”, Nat Biotechnol, 42 (3), 406-412
Waters, A., Liu, Q., Ji, X., Yasui, Y., Yabroff, K., Conti, R., Henderson, T., Huang, I., Leisenring, W., Armstrong, G., Nathan, P., Park, E., Kirchhoff, A. (2024). “Job lock among survivors of childhood cancer and their spouses post Affordable Care Act implementation: A Childhood Cancer Survivor Study brief report.”, Pediatr Blood Cancer, 71 (2), e30790-
Wong, C., Li, D., Wang, N., Gruber, J., Lo, A., Conti, R. (2023). “The estimated annual financial impact of gene therapy in the United States.”, Gene Ther, 30 (10-11), 761-773
Ohlsen, T., Wang, H., Buchbinder, D., Huang, I., Desai, A., Zheng, Z., Kirchhoff, A., Park, E., Krull, K., Conti, R., Yasui, Y., Leisenring, W., Armstrong, G., Yabroff, R., Nathan, P., Chow, E. (2023). “Financial hardship among siblings of long-term survivors of childhood cancer: A Childhood Cancer Survivor Study (CCSS) report.”, Journal of Clinical Oncology, 41 (16_suppl), 10048-10048
Chua, K., Nguyen, T., Zhang, J., Conti, R., Lagisetty, P., Bohnert, A. (2023). “Trends in Buprenorphine Initiation and Retention in the United States, 2016-2022.”, JAMA, 329 (16), 1402-1404
Hager, A., Gracia, G., Rodin, D., Conti, R. (2023). “Out-of-Pocket Costs of Treatment Among Employer-Insured Women With Invasive Breast Cancer.”, JAMA Netw Open, 6 (3), e231507-
Nathan, P., Huang, I., Chen, Y., Henderson, T., Park, E., Kirchhoff, A., Robison, L., Krull, K., Leisenring, W., Armstrong, G., Conti, R., Yasui, Y., Yabroff, K. (2023). “Financial Hardship in Adult Survivors of Childhood Cancer in the Era After Implementation of the Affordable Care Act: A Report From the Childhood Cancer Survivor Study.”, J Clin Oncol, 41 (5), 1000-1010
Becker, N., Seelye, S., Chua, K., Echevarria, K., Conti, R., Prescott, H. (2023). “Dispensing of Ivermectin From Veterans Administration Pharmacies During the COVID-19 Pandemic.”, JAMA Netw Open, 6 (2), e2254859-
Chua, K., Conti, R. (2023). “Out-of-Pocket Spending on Epinephrine Auto-Injectors Among the Privately Insured, 2015-2019.”, J Gen Intern Med, 38 (2), 538-541
Akesson, J., Weiss, E., Sae-Hau, M., Gracia, G., Lee, M., Culp, L., Connell, B., Butterfield, S., Conti, R. (2023). “COVID-19 Vaccine-Related Beliefs and Behaviors Among Patients With and Survivors of Hematologic Malignancies.”, JCO Oncol Pract, 19 (2), e167-e175
Auty, S., Griffith, K., Shafer, P., Gee, R., Conti, R. (2022). “Improving Access to High-Value, High-Cost Medicines: The Use of Subscription Models to Treat Hepatitis C Using Direct-Acting Antivirals in the United States.”, J Health Polit Policy Law, 47 (6), 691-708
Frank, R., Conti, R., Gruber, J. (2022). “International Reference Pricing in the Context of US Drug Policy.”, J Health Polit Policy Law, 47 (6), 779-796
Levengood, T., Aronsohn, A., Chua, K., Conti, R. (2022). “Dispensing of HIV and Hepatitis C Antivirals During COVID-19: An Interrupted Time-Series Analysis of U.S. National Data.”, Am J Prev Med, 63 (4), 532-542
Smith, G., Banegas, M., Acquati, C., Chang, S., Chino, F., Conti, R., Greenup, R., Kroll, J., Liang, M., Pisu, M., Primm, K., Roth, M., Shankaran, V., Yabroff, K. (2022). “Navigating financial toxicity in patients with cancer: A multidisciplinary management approach.”, CA Cancer J Clin, 72 (5), 437-453
Corrigan, K., Fu, S., Chen, Y., Kaiser, K., Roth, M., Peterson, S., Shih, Y., Jagsi, R., Giordano, S., Volk, R., Yabroff, K., Banegas, M., Acquati, C., Conti, R., Ma, H., Ku, K., You, Y., Smith, G. (2022). “Financial toxicity impact on younger versus older adults with cancer in the setting of care delivery.”, Cancer, 128 (13), 2455-2462
Rodin, D., Rosenthal, M., McGlave, C., Bhaskar, A., To, C., Conti, R. (2022). “National trends in post-launch cancer prescription drug prices and the impact of generic entry, 2014-2020.”, Journal of Clinical Oncology, 40 (16_suppl), 6598-6598
Rodin, D., Rosenthal, M., McGlave, C., Bhaskar, A., To, C., Conti, R. (2022). “National trends in post-launch cancer prescription drug prices and the impact of generic entry, 2014-2020.”, JOURNAL OF CLINICAL ONCOLOGY, 40 (16)
Mattingly, T., Conti, R. (2022). “Ensuring a high-quality and resilient supply chain of essential medications means paying more.”, J Manag Care Spec Pharm, 28 (5), 573-576
Volerman, A., Pelczar, A., Conti, R., Ciaccio, C., Chua, K. (2022). “Association between dispensing of low-value oral albuterol and removal from Medicaid preferred drug lists.”, BMC Health Serv Res, 22 (1), 562-
Chua, K., Dahlem, C., Nguyen, T., Brummett, C., Conti, R., Bohnert, A., Dora-Laskey, A., Kocher, K. (2022). “Naloxone and Buprenorphine Prescribing Following US Emergency Department Visits for Suspected Opioid Overdose: August 2019 to April 2021.”, Ann Emerg Med, 79 (3), 225-236
Chua, K., Conti, R., Becker, N. (2022). “US Insurer Spending on Ivermectin Prescriptions for COVID-19.”, JAMA, 327 (6), 584-587
Chua, K., Conti, R., Becker, N. (2022). “Trends in and Factors Associated With Out-of-Pocket Spending for COVID-19 Hospitalizations From March 2020 to March 2021.”, JAMA Netw Open, 5 (2), e2148237-
Chua, K., Fendrick, A., Conti, R., Moniz, M. (2022). “Out-of-Pocket Spending for Deliveries and Newborn Hospitalizations Among the Privately Insured”, Obstetrical & Gynecological Survey, 77 (1), 11-13
Killelea, A., Johnson, J., Dangerfield, D., Beyrer, C., McGough, M., McIntyre, J., Gee, R., Ballreich, J., Conti, R., Horn, T., Pickett, J., Sharfstein, J. (2022). “Financing and Delivering Pre-Exposure Prophylaxis (PrEP) to End the HIV Epidemic.”, J Law Med Ethics, 50 (S1), 8-23
Ballreich, J., Levengood, T., Conti, R. (2022). “Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV.”, J Law Med Ethics, 50 (S1), 32-39
Sharfstein, J., Conti, R., Gee, R. (2022). “From COVID Vaccines to HIV Prevention: Pharmaceutical Financing and Distribution for the Public’s Health.”, J Law Med Ethics, 50 (S1), 29-31
Conti, R., Frank, R., Nichols, L. (2021). “How Do Commercial Insurance Plans Fare Under Proposed Prescription Drug Price Regulation?”, JAMA Health Forum, 2 (12), e214242-
Maldonado, J., Fu, S., Chen, Y., Acquati, C., Yabroff, K., Banegas, M., Chang, S., Conti, R., Checka, C., Peterson, S., Advani, P., Ku, K., Jagsi, R., Giordano, S., Volk, R., Shih, Y., Smith, G. (2021). “Sensitivity of Psychosocial Distress Screening to Identify Cancer Patients at Risk for Financial Hardship During Care Delivery.”, JCO Oncol Pract, 17 (12), e1856-e1865
Conti, R., Frank, R., Gruber, J. (2021). “Regulating Drug Prices while Increasing Innovation.”, N Engl J Med, 385 (21), 1921-1923
Chua, K., Conti, R. (2021). “Prescriptions for Codeine or Hydrocodone Cough and Cold Medications to US Children and Adolescents Following US Food and Drug Administration Safety Communications.”, JAMA Netw Open, 4 (11), e2134142-
Chua, K., Conti, R., Becker, N. (2021). “Assessment of Out-of-Pocket Spending for COVID-19 Hospitalizations in the US in 2020.”, JAMA Netw Open, 4 (10), e2129894-
Chua, K., Brummett, C., Conti, R., Bohnert, A. (2021). “Opioid Prescribing to US Children and Young Adults in 2019.”, Pediatrics, 148 (3)
Chua, K., Volerman, A., Conti, R. (2021). “Prescription Drug Dispensing to US Children During the COVID-19 Pandemic.”, Pediatrics, 148 (2)
Mattingly, T., Seo, D., Ostrovsky, A., Vanness, D., Conti, R. (2021). “60 Years after Kefauver: Household income required to buy prescription drugs in the United States and abroad.”, Res Social Adm Pharm, 17 (8), 1489-1495
Conti, R., Padula, W., Becker, R., Salamone, S. (2021). “The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia.”, J Manag Care Spec Pharm, 27 (8), 1077-1085
Chua, K., Fendrick, A., Conti, R., Moniz, M. (2021). “Prevalence and Magnitude of Potential Surprise Bills for Childbirth.”, JAMA Health Forum, 2 (7), e211460-
Chua, K., Fendrick, A., Conti, R., Moniz, M. (2021). “Out-of-Pocket Spending for Deliveries and Newborn Hospitalizations Among the Privately Insured.”, Pediatrics, 148 (1)
Conti, R., McCue, S., Dockter, T., Rapkin, B., Dusetzina, S., Bennett, A., Gracia, G., Johnson, M., Martin, S., Chang, G., Richardson, P., Behrens, R., Weiss, E. (2021). “Assessing financial difficulty in patients with multiple myeloma: Preliminary results of ALLIANCE A231602CD.”, Journal of Clinical Oncology, 39 (15_suppl), 8031-8031
Nathan, P., Huang, I., Chen, Y., Henderson, T., Park, E., Kirchhoff, A., Robison, L., Krull, K., Armstrong, G., Leisenring, W., Conti, R., Yasui, Y., Yabroff, R. (2021). “Financial hardship in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).”, Journal of Clinical Oncology, 39 (15_suppl), 10026-10026
Conti, R., Lo, A., Wong, C., Gruber, J. (2021). “Estimating the Financial Impact of Gene Therapy in the U.S.”,
Chua, K., Conti, R. (2021). “Out-of-Pocket Spending for Influenza Hospitalizations in Medicare Advantage.”, Am J Prev Med, 60 (4), 537-541
Chua, K., Kimmel, L., Conti, R. (2021). “Spending For Orphan Indications Among Top-Selling Orphan Drugs Approved To Treat Common Diseases.”, Health Aff (Millwood), 40 (3), 453-460
Conti, R., Turner, A., Hughes-Cromwick, P. (2021). “Projections of US Prescription Drug Spending and Key Policy Implications.”, JAMA Health Forum, 2 (1), e201613-
Chua, K., Lee, J., Conti, R. (2021). “Potential Change in Insulin Out-of-Pocket Spending Under Cost-Sharing Caps Among Pediatric Patients With Type 1 Diabetes.”, JAMA Pediatr, 175 (1), 90-92
Padula, W., Parasrampuria, S., Socal, M., Conti, R., Anderson, G. (2020). “Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US”.”, Pharmacoeconomics, 38 (12), 1375-1376
Chua, K., Conti, R. (2020). “Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19.”, JAMA Intern Med, 180 (10), 1273-1274
Padula, W., Parasrampuria, S., Socal, M., Conti, R., Anderson, G. (2020). “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US.”, Pharmacoeconomics, 38 (10), 1115-1121
Chua, K., Conti, R. (2020). “Trends In Orphan Drug Spending And Out-Of-Pocket Spending Among US Children, 2013-18.”, Health Aff (Millwood), 39 (10), 1806-1811
Chua, K., Lee, J., Conti, R. (2020). “Out-of-Pocket Spending for Insulin, Diabetes-Related Supplies, and Other Health Care Services Among Privately Insured US Patients With Type 1 Diabetes.”, JAMA Intern Med, 180 (7), 1012-1014
Kimmel, L., Conti, R., Volerman, A., Chua, K. (2020). “Pediatric Orphan Drug Indications: 2010-2018.”, Pediatrics, 145 (4)
Nikpay, S., Buntin, M., Conti, R. (2020). “Relationship between initiation of 340B participation and hospital safety-net engagement.”, Health Serv Res, 55 (2), 157-169
Conti, R., Dusetzina, S., Sachs, R. (2020). “How The ACA Reframed The Prescription Drug Market And Set The Stage For Current Reform Efforts.”, Health Aff (Millwood), 39 (3), 445-452
Chua, K., Brummett, C., Conti, R., Bohnert, A. (2020). “Association of Opioid Prescribing Patterns With Prescription Opioid Overdose in Adolescents and Young Adults.”, JAMA Pediatr, 174 (2), 141-148
Chua, K., Schwartz, A., Volerman, A., Conti, R., Huang, E. (2020). “Differences in the Receipt of Low-Value Services Between Publicly and Privately Insured Children.”, Pediatrics, 145 (2)
Fox, E., Conti, R. (2020). “Pharmacy Forecast 2020: Pharmaceutical Supply Chain”, AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 77 (2), 101-103
Vermeulen, L., Swarthout, M., Alexander, G., Ginsburg, D., Pritchett, K., White, S., Tryon, J., Emmerich, C., Nesbit, T., Greene, W., Fox, E., Conti, R., Scott, B., Sheehy, F., Melby, M., Lantzy, M., Hoffman, J., Knoer, S., Zellmer, W. (2020). “ASHP Foundation Pharmacy Forecast 2020: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems.”, Am J Health Syst Pharm, 77 (2), 84-112
Conti, R., David, F. (2020). “Public research funding and pharmaceutical prices: do Americans pay twice for drugs?”, F1000Res, 9 707-
Woo, J., Anderson, B., Gruenstein, D., Conti, R., Chua, K. (2019). “Minimum Travel Distance Among Publicly Insured Infants with Severe Congenital Heart Disease: Potential Impact of In-state Restrictions.”, Pediatr Cardiol, 40 (8), 1599-1608
Chen, A., Hu, X., Conti, R., Jena, A., Goldman, D. (2019). “Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017.”, Value Health, 22 (12), 1387-1395
Conti, R., Berndt, E., Shivdasani, Y., Kaygisiz, N. (2019). “The Geography of Prescription Pharmaceuticals Supplied to the U.S.: Levels, Trends and Implications”,
Conti, R. (2019). “Financial Toxicity of Prescription Drugs.”, Ann Intern Med, 171 (9), 665-666
Conti, R., Berndt, E., Adajar, P. (2019). “The Surprising Hybrid Pedigree of Measures of Diversity and Economic Concentration”,
Conti, R., Nikpay, S., Buntin, M. (2019). “Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016”, JAMA Network Open, 2 (10), e1914141-e1914141
Conti, R. (2019). “3 Things You Need to Know About Prescription Drug Affordability”, Institute for Health System Innovation & Policy
Conti, R. (2019). “The Orphan Drug Act: IHSIP Expertise in Policy Action”,
Conti, R., Berndt, E. (2019). “Four Facts Concerning Competition in US Generic Prescription Drug Markets”, International Journal of the Economics of Business 1-22
Conti, R., Berndt, E. (2019). “Four Facts Concerning Competition in U.S. Generic Prescription Drug Markets”,
Conti, R., Kleutghen, P. (2019). “Is ‘Competitive Licensing’ Proposed In HR 1046 Practical For Lowering Drug Prices?”, Health Affairs
Conti, R., Chua, K. (2019). “Orphan Drugs For Opioid Use Disorder: An Abuse Of The Orphan Drug Act”, Health Affairs
Royce, T., Kircher, S., Conti, R. (2019). “Pharmacy Benefit Manager Reform”, JAMA, 322 (4), 299-299
Conti, R., David, F. (2019). “Rebalancing High Prescription Drug Prices With Innovation Incentives”, Health Affairs
Chua, K., Brummett, C., Conti, R., Haffajee, R., Prosser, L., Bohnert, A. (2019). “Assessment of Prescriber and Pharmacy Shopping Among the Family Members of Patients Prescribed Opioids”, JAMA Network Open, 2 (5), e193673-e193673
Chua, K., Conti, R. (2019). “Out-of-pocket Spending on Orphan Drug Prescriptions Among Commercially Insured Adults in 2014”, Journal of General Internal Medicine, 34 (3), 338-340
GaBI Journal Editor, . (2018). “US generic prescription drug markets 2004–2016”, Generics and Biosimilars Initiative Journal, 7 (4), 164-164
Parsons, S., Castellino, S., Rodday, A., Keller, F., Kelly, K., Conti, R., Lerner, D., Henderson, T. (2018). “Productivity Loss Among Parent Caregivers Is Associated with Poor Health-Related Quality of Life (HRQL) at the Intial Diagnosis of Pediatric Advanced Stage Hodgkin Lymphoma (HL)”, Blood, 132 (Supplement 1), 975-975
Conti, R., Nikpay, S., Buntin, M. (2018). “Diversity of Participants in the 340B Drug Pricing Program for US Hospitals”, Journal of the American Medical Association Internal Medicine, 178 (8), 1124-1127
Conti, R., Nguyen, K., Rosenthal, M. (2018). “Generic Prescription Drug Price Increases: Which Products Will Be Affected by Proposed Anti-Gouging Legislation”, Journal of Pharmaceutical Policy and Practice, 11 (1), 29-29
Conti, R., Chua, K. (2018). “Out-of-Pocket Spending on Orphan Drug Prescriptions Among Commercially Insured Adults in 2014”, Journal of General Internal Medicine, 178 (4), 133-140
(2018). “AMCP Partnership Forum: Driving Value and Outcomes in Oncology.”, J Manag Care Spec Pharm, 24 (6), 572-578
Parsons, S., Lerner, D., Rodday, A., Curtis, R., Kelly, K., Conti, R., Castellino, S., Henderson, T. (2018). “Parental work limitations at diagnosis of advanced stage pediatric Hodgkin lymphoma—Results of caregiver work limitations questionnaire (CG WLQ).”, Journal of Clinical Oncology, 36 (15_suppl), e18927-e18927
Berndt, E., Conti, R., Murphy, S. (2018). “The generic drug user fee amendments: an economic perspective”, Journal of Law and the Biosciences, 5 (1), 103-141
Aggarwal, M., Devries, S., Freeman, A., Ostfeld, R., Gaggin, H., Taub, P., Rzeszut, A., Allen, K., Conti, R. (2018). “The Deficit of Nutrition Education of Physicians.”, Am J Med, 131 (4), 339-345
Conti, R., Berndt, E. (2018). Specialty Drug Prices and Utilization after Loss of U.S. Patent Exclusivity, 2001–2007. In David, Cutler. (Eds.), “Measuring and Modeling Health Care Costs Advances in CRIW Conference Proceedings”, University of Chicago Press
Conti, R., Chua, K., Shrime, M. (2017). “Effect of FDA Investigation on Opioid Prescribing to Children after Tonsillectomy/Adenoidectomy”, Pediatrics, 140 (6), 6-6
Conti, R. (2017). “Making Medicines Affordable: A National Imperative — A Review”, Health Affairs
Conti, R., Nikpay, S., Buntin, M. (2017). “The 340B Program: Mandatory Reporting, Alternative Eligibility Criteria Should Be Top Priorities for Congress”, Health Affairs
Dusetzina, S., Conti, R., Yu, N., Bach, P. (2017). “Association of Prescription Drug Price Rebates in Medicare Part D with Patient Out-of-Pocket and Federal Spending”, Journal of the American Medical Association Internal Medicine, 177 (8), 1185-1188
Conti, R. (2017). “Biosimilars: Reimbursement Issues in Your Oncology Practice”, Journal of Oncology Practice, 13 (9), 12-14
Conti, R., DeSouza, J. (2017). “Mitigating Financial Toxicity among US Patients with Cancer”, Journal of the American Medical Association Oncology, 3 (6), 765-766
Conti, R. (2017). “Biosimilars: Reimbursement Issues in Your Oncology Practice.”, Journal of oncology practice, 13 (9_suppl), 12s-14s
Conti, R., Berndt, E. (2017). “The Generic Drug User Fee Amendments: An Economic Perspective”,
Conti, R., Murphy, S., Berndt, E. (2017). “The Landscape of US Generic Prescription Drug Markets, 2004–2016”, The National Bureau of Economic Research
Conti, R., Chua, K. (2017). “Out-of-Pocket Spending among Commercially Insured Patients for Epinephrine Autoinjectors between 2007 and 2014”, Journal of the American Medical Association Internal Medicine, 176 (2), 736-739
Chua, K., Conti, R. (2017). “Out-of-Pocket Spending Among Commercially Insured Patients for Epinephrine Autoinjectors Between 2007 and 2014.”, JAMA Intern Med, 177 (5), 736-739
Conti, R., Jones, D. (2017). “Policy Diffusion across Disparate Disciplines: Private- and Public-Sector Dynamics Affecting State-Level Adoption of the ACA”, Journal of Health Politics, Policy and Law, 42 (2), 377-385
Chua, K., Conti, R., Freed, G. (2017). “Appropriately Framing Child Health Care Spending: A Prerequisite for Value Improvement”,
Conti, R., padula, w. (2017). Changing the Cost of Care for Chronic Myeloid Leukemia: The Availability of Generic Imatinib in the U.S. and the E.U.. In Richard, Hehlmann. (Eds.), “Chronic Myeloid Leukemia: What Every Clinical Practitioner Needs to Know in 2017”, ASCO
Dragoni, F., Conti, R., Cazzaniga, S., Colucci, R., Pisaneschi, L., Naldi, L., Moretti, S. (2017). “No Association between Vitiligo and Obesity: A Case-Control Study.”, Med Princ Pract, 26 (5), 421-426
Henderson, T., Castellino, S., Keller, F., Kelly, K., Curtis, R., Conti, R., Parsons, S. (2016). “Approach and Feasibility of Patient-Reported Outcomes (PROs) in a Phase III Clinical Trial for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Children and Adolescents”, Blood, 128 (22), 3583-3583
Darlington, W., Watson, S., Henderson, T., Cunningham, J., Conti, R. (2016). “The Affordable Care Act Improves Healthcare Access and Utilization Among Young Adults with Sickle Cell Disease”, Blood, 128 (22), 4747-4747
Chua, K., Schwartz, A., Volerman, A., Conti, R., Huang, E. (2016). “Use of Low-Value Pediatric Services Among the Commercially Insured”, PEDIATRICS, 138 (6), e20161809-e20161809
Conti, R., Gee, R., Sharfstein, J. (2016). “Pharmaceuticals and Public Health.”, JAMA, 316 (20), 2083-2084
Pitts, P., Louet, H., Moride, Y., Conti, R. (2016). “21st century pharmacovigilance: efforts, roles, and responsibilities.”, Lancet Oncol, 17 (11), e486-e492
Castellino, S., Henderson, T., Keller, F., Kelly, K., Curtis, R., Conti, R., Parsons, S. (2016). “APPROACH AND FEASIBILITY OF PATIENT-REPORTED OUTCOMES IN A PHASE III CLINICAL TRIAL FOR ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN CHILDREN AND ADOLESCENTS”, HAEMATOLOGICA, 101 37-37
Conti, R. (2016). “The Advantages of Awarding the Federal Government Negotiating Power Over the Prices of Prescription Drugs”, Journal of Policy Analysis and Management, 35 (4), 964-970
Conti, R. (2016). “Response to Joyce and Sood”, Journal of Policy Analysis and Management, 35 (4), 972-974
Padula, W., Larson, R., Dusetzina, S., Apperley, J., Hehlmann, R., Baccarani, M., Eigendorff, E., Guilhot, J., Guilhot, F., Hehlmann, R., Mahon, F., Martinelli, G., Mayer, J., Müller, M., Niederwieser, D., Saussele, S., Schiffer, C., Silver, R., Simonsson, B., Conti, R. (2016). “Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.”, J Natl Cancer Inst, 108 (7)
Polite, B., Ward, J., Cox, J., Morton, R., Hennessy, J., Page, R., Conti, R. (2016). “A Pathway Through the Bundle Jungle.”, J Oncol Pract, 12 (6), 504-509
Weiner, A., Conti, R., Eggener, S. (2016). “National Economic Conditions and Patient Insurance Status Predict Prostate Cancer Diagnosis Rates and Management Decisions.”, J Urol, 195 (5), 1383-1389
Clark, B., Hou, J., Huang, E., Conti, R., Chou, C. (2016). “Medication Adherence among Hiv/Aids Patients Receiving 340b-Purchased Antiretroviral Medications”, Value in Health, 19 (3), A8-A8
Bach, P., Conti, R., Muller, R., Schnorr, G., Saltz, L. (2016). “Overspending driven by oversized single dose vials of cancer drugs.”, BMJ, 352 i788-
Conti, R., Rosenthal, M. (2016). “Pharmaceutical Policy Reform–Balancing Affordability with Incentives for Innovation.”, N Engl J Med, 374 (8), 703-706
Dusetzina, S., Ellis, S., Freedman, R., Conti, R., Winn, A., Chambers, J., Alexander, G., Huskamp, H., Keating, N. (2015). “How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab.”, J Oncol Pract, 11 (4), 313-318
Padula, W., Larson, R., Conti, R., Dusetzina, S. (2015). “Comparing tyrosine kinase inhibitor treatment strategies for newly diagnosed chronic myeloid leukemia in chronic phase when imatinib loses patent exclusivity in the u.s.: a cost-effectiveness analysis”, Value in Health, 18 (3), A205-A205
Polite, B., Ward, J., Cox, J., Morton, R., Hennessy, J., Page, R., Conti, R. (2015). “Reply to M. Thompson et Al.”, J Oncol Pract, 11 (3), 263-264
Conti, R., Padula, W., Larson, R. (2015). “Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.”, Ann Hematol, 94 Suppl 2 (0 2), S249-S257
Gibbons, R., Coca Perraillon, M., Hur, K., Conti, R., Valuck, R., Brent, D. (2015). “Antidepressant treatment and suicide attempts and self-inflicted injury in children and adolescents.”, Pharmacoepidemiol Drug Saf, 24 (2), 208-214
Conti, R. (2015). “Expanding the Scope of the National Practice Oncology Benchmark Would Be a Critical Source for Understanding Outpatient Oncology Practice Costs and Profits in a Time of Change.”, J Oncol Pract, 11 (1), e95-e97
Polite, B., Conti, R., Ward, J. (2015). “Reform of the Buy-and-Bill System for Outpatient Chemotherapy Care Is Inevitable: Perspectives from an Economist, a Realpolitik, and an Oncologist.”, Am Soc Clin Oncol Educ Book e75-e80
Howard, D., Bach, P., Berndt, E., Conti, R. (2015). “Pricing in the Market for Anticancer Drugs.”, J Econ Perspect, 29 (1), 139-162
Larson, R., Conti, R., Padula, W., Apperley, J., Baccarani, M., Eigendorff, E., Guilhot, F., Guilhot, J., Mahon, F., Martinelli, G., Mayer, J., Mueller, M., Niederwieser, D., Saussele, S., Schiffer, C., Silver, R., Simonsson, B., Hehlmann, R. (2014). “What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?”, Blood, 124 (21), 738-738
Polite, B., Ward, J., Cox, J., Morton, R., Hennessy, J., Page, R., Conti, R. (2014). “Payment for oncolytics in the United States: a history of buy and bill and proposals for reform.”, J Oncol Pract, 10 (6), 357-362
Conti, R., Bach, P. (2014). “Improving outpatient oncology practice: several steps into a long journey.”, J Oncol Pract, 10 (6), 355-356
Clark, B., Hou, J., Chou, C., Huang, E., Conti, R. (2014). “The 340B discount program: outpatient prescription dispensing patterns through contract pharmacies in 2012.”, Health Aff (Millwood), 33 (11), 2012-2017
Padula, W., Conti, R., Larson, R. (2014). “What is the Most Cost-Effective Strategy for Treating Chronic Myeloid Leukemia After Imatinib Loses Patent Exclusivity in Europe?”, Value Health, 17 (7), A636-
Dusetzina, S., Winn, A., Chambers, J., Ellis, S., Conti, R., Freedman, R., Alexander, G., Keating, N., Huskamp, H. (2014). “Payer-Level Differences in the Response to Regulatory Actions Regarding Withdrawal of Breast Cancer as an Indication for Bevacizumab”, JOURNAL OF WOMENS HEALTH, 23 (10), 857-857
Conti, R., Fein, A., Bhatta, S. (2014). “National trends in spending on and use of oral oncologics, first quarter 2006 through third quarter 2011.”, Health Aff (Millwood), 33 (10), 1721-1727
Conti, R., Bach, P. (2014). “The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities.”, Health Aff (Millwood), 33 (10), 1786-1792
Howard, D., Conti, R. (2014). “Are new drugs more expensive than old ones? Trends in the benefit-adjusted launch prices of anticancer drugs, 1995-2013.”, Journal of Clinical Oncology, 32 (15_suppl), 6525-6525
Goldberg, P., Conti, R. (2014). “Problems with public reporting of cancer quality outcomes data.”, J Oncol Pract, 10 (3), 215-218
Conti, R. (2013). “Drug discount program–reply.”, JAMA, 310 (15), 1627-
Conti, R., Dusetzina, S., Herbert, A., Berndt, E., Huskamp, H., Keating, N. (2013). “The impact of emerging safety and effectiveness evidence on the use of physician-administered drugs: the case of bevacizumab for breast cancer.”, Med Care, 51 (7), 622-627
Conti, R., Bach, P. (2013). “Cost consequences of the 340B drug discount program.”, JAMA, 309 (19), 1995-1996
Kornfield, R., Watson, S., Higashi, A., Conti, R., Dusetzina, S., Garfield, C., Dorsey, E., Huskamp, H., Alexander, G. (2013). “Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008.”, Psychiatr Serv, 64 (4), 339-346
Conti, R., Bernstein, A., Villaflor, V., Schilsky, R., Rosenthal, M., Bach, P. (2013). “Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.”, J Clin Oncol, 31 (9), 1134-1139
Bhatta, S., Fein, A., Conti, R. (2013). “TRENDS IN SPENDING ON ORAL CHEMOTHERAPEUTIC AGENTS 2006-2012”, CLINICAL PHARMACOLOGY & THERAPEUTICS, 93 S12-S12
Dusetzina, S., Busch, A., Conti, R., Donohue, J., Alexander, G., Huskamp, H. (2012). “Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory.”, Pharmacoepidemiol Drug Saf, 21 (12), 1251-1260
Dusetzina, S., Higashi, A., Dorsey, E., Conti, R., Huskamp, H., Zhu, S., Garfield, C., Alexander, G. (2012). “Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review.”, Med Care, 50 (6), 466-478
Conti, R., Rosenthal, M., Polite, B., Bach, P., Shih, Y. (2012). “Infused chemotherapy use in the elderly after patent expiration.”, Am J Manag Care, 18 (5), e173-e178
Conti, R., Rosenthal, M., Polite, B., Bach, P., Shih, Y. (2012). “Infused chemotherapy use in the elderly after patent expiration.”, J Oncol Pract, 8 (3 Suppl), e18s-e23s
Philipson, T., Eber, M., Lakdawalla, D., Corral, M., Conti, R., Goldman, D. (2012). “An analysis of whether higher health care spending in the United States versus Europe is ‘worth it’ in the case of cancer.”, Health Aff (Millwood), 31 (4), 667-675
Pillarella, J., Higashi, A., Alexander, G., Conti, R. (2012). “Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, 1998-2009.”, Psychiatr Serv, 63 (1), 83-86
Garfield, C., Dorsey, E., Zhu, S., Huskamp, H., Conti, R., Dusetzina, S., Higashi, A., Perrin, J., Kornfield, R., Alexander, G. (2012). “Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000-2010.”, Acad Pediatr, 12 (2), 110-116
Conti, R., Bernstein, A., Meltzer, D. (2012). “How do initial signals of quality influence the diffusion of new medical products? The case of new cancer drug treatments.”, Adv Health Econ Health Serv Res, 23 123-148
Dusetzina, S., Alexander, G., Conti, R., Dorsey, E., Higashi, A., Zhu, S., Garfield, C., Huskamp, H. (2011). “Predictors of High Metabolic Risk Antipsychotic Use”, PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 20 S264-S264
Garfield, C., Dorsey, E., Zhu, S., Higashi, A., Huskamp, H., Conti, R., Dusetzina, S., Alexander, G. (2011). “US Trends in the Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder, 2000-2010”, PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 20 S197-S197
Conti, R. (2011). “Overuse of Antidepressants in a Nationally Representative Adult Patient Population in 2005”, Psychiatric Services, 62 (7), 720-720
Conti, R., Busch, A., Cutler, D. (2011). “Overuse of antidepressants in a nationally representative adult patient population in 2005.”, Psychiatr Serv, 62 (7), 720-726
Alexander, G., Garfield, C., Dorsey, R., Zhu, S., Higashi, A., Huskamp, H., Conti, R., Dusetzina, S. (2011). “US TRENDS IN THE DIAGNOSIS AND TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER, 2000-2010”, JOURNAL OF GENERAL INTERNAL MEDICINE, 26 S253-S253
Qato, D., Lindau, S., Conti, R., Schumm, L., Alexander, G. (2010). “Racial and ethnic disparities in cardiovascular medication use among older adults in the United States.”, Pharmacoepidemiol Drug Saf, 19 (8), 834-842
Conti, R. (2010). “Advances in economics to further inform investments in vaccine development”, Human Vaccines, 6 (4), 286-291
Conti, R. (2010). “Advances in economics to further inform investments in vaccine development.”, Hum Vaccin, 6 (4), 289-291
Dorsey, R., Rabbani, A., Gallagher, S., Conti, R., Alexander, G. (2010). “IMPACT OF FDA BLACK BOX ADVISORY ON ANTIPSYCHOTIC MEDICATION USE”, JOURNAL OF INVESTIGATIVE MEDICINE, 58 (4), 675-675
Dorsey, E., Rabbani, A., Gallagher, S., Conti, R., Alexander, G. (2010). “Impact of FDA black box advisory on antipsychotic medication use.”, Arch Intern Med, 170 (1), 96-103
Conti, R., Veenstra, D., Armstrong, K., Lesko, L., Grosse, S. (2010). “Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities.”, Med Decis Making, 30 (3), 328-340
Meltzer, D., Basu, A., Conti, R. (2010). “The economics of comparative effectiveness studies: societal and private perspectives and their implications for prioritizing public investments in comparative effectiveness research.”, Pharmacoeconomics, 28 (10), 843-853
Conti, R., Banks, J., Cornaglia, F. (2009). “LABOUR MARKET PARTICIPATION AND DEPRESSIVE SYMPTOMS AT OLDER AGES IN THE US AND UK”, GERONTOLOGIST, 49 19-19
Qato, D., Lindau, S., Conti, R., Alexander, G. (2009). “PIH51 Racial/Ethnic Disparities in Prescription Drug Use Among Older Adults in the United States”, Value in Health, 12 (3), A171-A171
Conti, R. (2009). “Value of research analysis: an application to drug development.”, Clin Adv Hematol Oncol, 7 (5), 298-300
Qato, D., Alexander, G., Conti, R., Johnson, M., Schumm, P., Lindau, S. (2008). “Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States.”, JAMA, 300 (24), 2867-2878
Conti, R., Meltzer, D., Ratain, M. (2008). “Nonprofit biomedical companies.”, Clin Pharmacol Ther, 84 (2), 194-197
Conti, R. (2008). “The societal benefit of nonprofit biotechnology companies.”, Clin Adv Hematol Oncol, 6 (5), 366-386
Rosenthal, M., Landrum, M., Meara, E., Huskamp, H., Conti, R., Keating, N. (2007). “Using performance data to identify preferred hospitals.”, Health Serv Res, 42 (6 Pt 1), 2109-2119
Chien, A., Conti, R., Pollack, H. (2007). “A pediatric-focused review of the performance incentive literature.”, Curr Opin Pediatr, 19 (6), 719-725
Frank, R., Conti, R., Goldman, H. (2005). “Mental Health Policy and Psychotropic Drugs”, The Milbank Quarterly, 83 (2), 271-298
Epstein, A., Ayanian, J., Keogh, J., Noonan, S., Armistead, N., Cleary, P., Weissman, J., David-Kasdan, J., Carlson, D., Fuller, J., Marsh, D., Conti, R. (2000). “Racial disparities in access to renal transplantation–clinically appropriate or due to underuse or overuse?”, N Engl J Med, 343 (21), 1537-1544
Conti, R., Neumann, P., Gruber, J., Ollandorf, D. (2000). “Valuing Rare Pediatric Drugs: An Economics Perspective”,